• First-time occurrence or a history of stroke without significant neurological deficits (baseline mRS score ≤ 1).

• Eligible for treatment with intravenous administration of urokinase or alteplase as assessed by the investigators.

• Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable.

• \-